Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
UCB Pharma
This is the open-label extension to the randomized, double-blind, placebo-controlled SP512 trial that assessed the efficacy and safety and tolerability of the Rotigotine patch in subjects with early-stage idiopathic Parkinson's Disease.
Age
31–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects who have completed six months of maintenance treatment in the SP512 double-blind trial
You may not be if
Subjects who had an ongoing serious adverse event from SP512 double-blind trial that was assessed as related to study medication
